Edition:
United States

pSivida Corp (PSDV.OQ)

PSDV.OQ on NASDAQ Stock Exchange Global Market

1.19USD
11:53am EST
Change (% chg)

$0.01 (+0.85%)
Prev Close
$1.18
Open
$1.18
Day's High
$1.21
Day's Low
$1.18
Volume
17,165
Avg. Vol
67,119
52-wk High
$2.45
52-wk Low
$1.04

Select another date:

Tue, Nov 7 2017

BRIEF-pSivida reports Q1 loss per share of $0.15

* Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

BRIEF-pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

* pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

BRIEF-pSivida Corp reports Q4 loss per share $0.16

* pSivida Corp achieves significant milestones throughout fy 2017; reports fourth quarter and fiscal 2017 results

BRIEF-pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN

* pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN

BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis

* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation

BRIEF-Psivida submits marketing authorization application for approval of Durasert in EU

* Psivida submits marketing authorization application (maa) for approval of durasert™ three-year treatment for posterior segment uveitis in European Union

BRIEF-Psivida's Durasert successfully achieves primary efficacy endpoint in second phase 3 study

* Psivida's Durasert three-year treatment for posterior segment uveitis successfully achieves primary efficacy endpoint in second phase 3 study

Select another date: